Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]

  • Awaiting development
  • GID-TA10685
  • Expected publication date: TBC

Status:
Awaiting development
Decision:
None selected
Process:
TA
ID number:
3819

For further information on our processes and methods, please see our CHTE processes and methods manual